2024-08-31-accounts

REGISTERED COMPANY NUMBER: CE010848 {Engl8nd and Wales) REGI￿ERED CHARITY NUMBER: 1174374 POR FTH TRU ESA NA DITED FI AN IA STAT MENT FOR THE YEAR ENDED T 2024 OR TH I FOUN ATI Xeinadin South East Ltd CT¢Jle Business Hub Ground Floor 5 Rayleigh Road Hutton, Brentwood. Essex CM13 IAB

THEM DIF NDATION NT THEF AN FOR THE YEAR ENDED 31 A TEM UST 2024 Page Report ol the Tru$tee5 Independent Examlner's Report Statement of Fln4n¢lal Actlvlties Balanee Sheet 10 lo I I Notes to the Flnancial Statements 12 to 15 Detlllod Stjtement of Flftxnel&l Actlvltlel 16

HE MADDI UND TJON REPORT OF THE TR EYEARE TEES 024 Thc Iruste¢s who are also directors of the charity for the purposes of Ihe Companies Act 2006. presei)I their report with th¢ financtal slatem¢nls of the charity for tlie year ended 31 Au8USt 2024. The Iwslees havc adopted die provisions of Accounting and Reporting by Charities: Sthieinenl of Rccoinmended Praciice applicable lo cliarilies pryaring their accounts in accordance with the Financial Reporting Standard Applicable in the UK and Republic of Ireland (FRS 1021 (effective l January 2019). STRUCTUR& GOVERNANCE AND MANAGEMENT Governlng document The Charity is controlled by ils governing documenL a deed of trusL and conscitules a limiled company, limi*d by guaraote¢, as defined by Ihc Companies Act 2006. REFERENCE AND ADMINIST1￿TIvE DETAILS Reglstered Company numb¢r CEO10848 (England and Wales) Regls¢er¢d Charlty number 1174374 Reglstered offl¢e Xeinadin South¢abt Limited Create Business Hub Ground Floor, S Rayleigh Road Shenfield Brentwood CM13 IAB Page I

TH MAD I FOUNDA TION REP RT OF THE TRU YEAR END TEES 2024 Trustees FOR THE PERIOD I SEPTEMBER 2023 TO 31 AUGUST 2024 The trustees, who are also directors of the charity for the PUTposes of the Companies Act 2006, present th¢iT report with the financial slatemenls of the charity for the period I September 2023 to 31 August 2024. The mistecs have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice &pplicablc ¢0 ¢harilics preparing their account% in accordance with the Financial Reporting Siandgrd applicable in the UK and Republic of Ireland (FRS 102) (effective l January 2015). INCORPORATION The charitable coinpany was ii)corporated on 24 August 2017. STRUCTURE, GOVERNANCE AND MANAGEMENT Govemin8 document The ch&rily is controlled by ils governinB document, a Deed of T￿51. and con.81ilutes a limiied company, liiniicd by guaranlee, as defin￿ by the Companics Act 2006. The organisational structure of Ihe cliarity and how decisions are made. The boord of tNstee5 consisls of4 individuals as of 31 sl Augus(2024. Corina Thur8ood is CEO and 15 responsible for the day-lo-day organisation of tlie charily, workin8 ¢losely with oilier trust¢¢$ and managenient on decision making matters. REFERENCE AND At)MINISTRATIVE DETAILS Registered Company nliinber CEO10848 (England and Woles) Re8lStered Charity niiniber 1174374 Rcgislered office XLinadin South Easl Lid Create Business Hub 5 Raylei8h Road Shettfield Brentwood Essex CM13 IAB THE TRUSTEES Mrs Carina Thurgood Miss Alcxandra Thur8ood Miss Victoria Bissett Mr Hany Thurgood Reference and Adminislraiion Details Intr(￿UctIon from tlie Trus(¢es Th¢ Truslees of The Maddi Foundation are plcased to present tlie charity's founh annual review. covering Ihc financial ycar cnding 31 August 20?4. We confirn] that the Foundation has operated in full compliance wilh Ihe Charilics Act 201 l throughout the reporting period. About the Foundation The Maddi Fouiidation was founded in August 2017 by Carina and Alexandra T])urgood following tlie diagnosis of Carina's daughter and Alexandra's sister. Maddi, with SPG15. a rare, inherited neurode8¢n¢ralive disorder. during Ihe summer of 2016. Ai ihc iiine, Ihere was 110 UK-ba5ed organisation dedicated to Iupportinbp medical research into SPG15, a complex subtype of Heredilary Spaslic Paraplegia. The Foundation created lo fill ihts critical bpap and to provide hope for Maddi and others atTeGted by Ihis ulira-rare condilion. Governance and Oversighi Page 2

TH MA DI FOUNDATI REPORT OF THE TRUSTEES FOR T YE ENDED UST2 24 The Board of Trust¢¢s meets annually ai thc end of each financial year to review the charity's actlvllies, assess progress loward its strdte8i¢ objective5, and consider any necessary updates lo policies. procedures. or governance slructur¢s. This ongoing oversight ensures that the Foundation continues to operate effectively aT]d transparently in line wilh its cliariiable objectives. Our Focus and Aclivilies The Maddi Foundatioii is dedicated to fundin8 high-inipact medical research into SPGIS and Tclatcd rare gci)eti¢ coiidilions. Siiice our launch. we have primarily supported a long-lenn geiie therapy research ii)itiative in Ihe UK, while also building coni)eclions with researchers in Europe and the United Slat¢s lo explore additional colljboraiive opportunities. In parallel with our research efforts, we are committed lo raisiiig awareness of SPG15 through participation in rare dilieasc iielwork4 as well as via OLir wcb5it¢ and social mcdia plaiforms. By increasing visibilily and ¢ngAgLment. we aim to reach more afTecl¢d familles. support knowledge-sharinB, and Slren¥ihLn the inteniAiioiial effort to find effcclive Ireaiments. THE MADDT FOUNDA TION REPORT OF T14E TRUSTEES FOR THE YEAR ENDED 31 AUGUST 2024 Our Mission and Grant-making Approach Since our establibhmcnl in 2017, our foundaiion ha?* b¢en comniilled lo advancing re￿IrCh inio Irclllmcnls for SPG15. r&r¢ and complex neurolo8i6Jl Londttion. Through d¢dical¢d fiindrnisiny Lfforts, including cominunity ev¢nts, donor caiJ)pgi¥ng, and institutional ¥rants, we have suc¢¢ssfully raised the financial t>UPPOrt nccL'ssary to drive forward sci¢ntific disLovery. Based in lh¢ UK, wc have built a slrong inlemalional network of rcsta￿hcr$, clinicians, and parln¢r or8unisations, particularly across EuiY)pe and the United Stales. Wc believc that 8lobal collaboration is ¢55cnlial to accelerating progress and acliieving meaningful breaktl?roughs in SPG15 researcli. Our gra￿t-makIng policy is firnily rooted in our Ini55ion to support innovalive and impactfiil researeh. All rcsearch graiits Arc fvnded through donations specificolly earmai'ked for SPG15. In assessing potential grant allocations. we work closely wilh Professor Mtmoiin Az7.ouz. a Icading expert in Il)e field of gene therapy. Professor Azzouz hcad5 Ihc research tcam at ihe Slieffield Insiitute for Translational Neuroscience (SITraN) scrv¢s as DircLlor of thc Genc Therapy Innovation and Manufacturing Cenirc (GTIMCI. If Slieffield Univ¢rsity is unable to Secure aliemative fundin8 for SPG15 research, our foundation seeps in to provide targeted financial suppon to his te8m's pioncering work. E8ch fundin8 d¢¢ision is review￿ and approved by our Board of Trustees in consultation with our sci¢ntific udvisory panel. This pr0¢¢55 ensurcs that all supported projects are scientifi¢Nlly sound and have Ihe poienliol to meaningfully conlribuie lo the development of cffeciive ireatsnenls for SPG I S. We remain deeply e¢>mmitlcd lo ensuring iliat ev¢ry grant iv¢ provide brings us closer to & future wliere those offccled by SPGI 5 liave access to viable therapies &nd improved qualily ofiife. Whal is SPG15'P SPGIS, or Spastic Paraplegia Type 15. is a rare and progressive iieurodegeiieralive disorder classified wiihiii tlie group of hcreditary spastic parjplegias (HSPS), 11 is also con5ider¢d a fonn of motor Iieui'oii disease, as it affects both the central and peripheral nervous systenis. SPG15 is caused by mutatioi)s iii ihe ZFYVE26 geiie, which plays a critical role in the health and funciion of nerve c¢ll5. Onsel lypicJlly occurs in childhood or adolescence, wilh early symptoms often including stiffness (spasticily) in (he leg8 and difficulty w&lkiiis'. As Ihc conditioii pro¥rc%ses. il can lead lo increasing paTalysis of the lower and upper liinbs, accompanicd by g¢veTe miiscle weakness and ¢oordinaiion dI￿l¢ll111¢s. In many casL's. individiials wilh SPG15 evLnlually becoine wheelchair dependenl. Page 3

THE MADDI F NDAT REPORT OF THE TRUSTEES THE R ENDED 24 Beyond moior impaimjent, SPG15 also in)pacts th¢ brain ni9￿ broadly, causing a rdll8e of neurological and cognitive issues. These may include thii)ning of the corpus callosum (a vital brain structure that connects the two hernispheres), causing learning difficulties. speech and langua8e delays. The disease can also affect visioii ihrough relinal degencTalion, impair liearing, and lead to urinary inconiinence. Sonie individuols may develop ¢arly-onsel parkin50nisn), a condition tliat mimics many fealures of Parkinson's disease. SPG15 is inherited in an aiitosoinal recessive pattern, Ineaning boih pAren15 Inust carry a copy of Ihe fauliy gcne for child to be affected. Due to ils rarity. SPG15 is often und¢rdiagnosed or niisdia8nos¢d. and awareness ainong healthcare providers remains limited. Currently, there is no cure or approved treatmenl for SPG15. Management is focused on relieving synipiom$ and maintaining mobility and quality of life tl)rou8h supportive care, including physioiherapy, occupational Iherapy, and assistive devices. Research 15 ongoing lo beller understond the underlying biology of the disease and to develop targeted Iherapi&s, in¢luiiing gene Iherapy. Raising awar¢nc¥b and fuiiding re>earcli ar¢ vilal si¢ps toward finding a cure and improvin¥ outcoiii¢s for individuals liviii8 with SPG I S Dnd iheir familie¥. Report of the Trustee5 For the year ending 31 Augiist 2024 W¢ present our report aloiiE with the financial slalements of Ihe Charity for the year ended 31 Augiisl 2024. The tNsiee.s have adopted the provisions of Accounting and Reporting by Charities: Siatenienl of R¢coinixended Practice applicablc io ¢hariiies p￿parIng thLir accounis in accordance wilh lh¢ Financial Reporting Standard applicable in Ihe UK and R¢piiblic of Ireland (FRS 102) (cffective l January 2015). Our Aims and Objectives Th¢ Maddi FoundJtion is fully commiiied to driving forward rcsearch into Her¢ditsry Spasti¢ Parmplegia Typc 15 (SPGIS}, with tl)¢ uliimale goal of identifying ai) effeciive ireatinent, and one day. a cure, Since our iii¢¢ption ii) 2017 we have worked closely with Ihc researcher5 leading Ihis vital work. ensuring Ihal our efforts arc 51rategicAlly aligneii with scientific dcvelopments. We believe colloboration is esseniial. and we aclively cngag¢ wilh clinicians. scienlisl$, and oil)er ror¢ diseas¢ or8Anisations across tl)e UK and inlemationally to accelerate progress. Our Defined Aims l.Raise Awaren¢ss'. Increase public and profcssional awareness of SPG15 and related hercdilary spastic P¢iraplegias by providing accurote, accessible, And Up-t￿dal¢ infoTmation through our wcbsile, social media channel$, and oulrcach initiatives. 2.Fund R¢seoreh: Generate and allocate fuiids to suppon cutliiig<d8e scientific and clinical researcli into tl)c CaU8e8, progression, and poieiili&l trealmcni of SPG I S, with a focus oli Ilierapeutic innovaiion. 3.Provide Resources and Build Cornmuniiy," Curate and share coinpr¢hen$ive resotsrces, includin8 pccr-reviewed research paper%. clinical trial updaies, and educational matcrials. We aiE also dedicated to fostering a supportive nclwork for families aiid individuals affected by SPG15, promoting kiiowledgc-sharin8 and mutual support. A Charitable Pu￿0.$C with Public Beiiefii When we esiabli8lied Th¢ Maddi Foundation, our first priorily w&$ to ensu￿ tl)g1 our Mims ¢lcarly served th¢ public inieresi. These objectives fonned the foundation of our &ppli¢aiion to becoine a Cliarilabl¢ Incorpordled Oryanisalion (CIO). a status ¥ranted by ilie Charily Coinmission iii recognition of our comniilinent lo public benefit. Page 4

THEM DJF IYDATION REPORT OF TH TRU TEES FOR THE Y REN ED UGUST 2024 In planning and delivering our aclivities, we adhere stricily to the Principl￿ outlined in the Charities Act 2011. We have followed all relevani guidance frorn tl)e Charity Commission. ¢nsuring our operalions consisienily meet tlie standards of transparency, accouniability, aiid impact expected of charitable organisations. The public benefit of the charity's aciivities i.s outlined under'our Aims and Objeclives, and 'Achievements and Perforniance,. Achievements and Peiforniance The MAddi Foundation is commilled io funding cutlin8-cdge nwdi¢ftl research lo develop effective IreaimcnL8 for SPG15, with the goal of haltin8 the progression of this devastalin8 disease. At presciil, many familie5 affected by SPGIS have no tffalmenl options lo slow the disease or improve qualiry of life. We are detern]ined lo change Il)at by supportiiig proinising scientific advances and forging strong collaborations with world-leading experts in the field. Our ProgTe5s So Far Since 2017. the Maddi Foundation has focused its efforts on advancing ¥ene Ilierapy as a Polenlial Irealmenl for SPG15. a rare neurologi￿] condition caused by the absence or dysfunciion of the SPG15 protein due to mulalions in Ihc ZFYVE26 ¥ene. Gene Ih¢rdPy is an innovative and evolving area of medicine that seeks lo replace or repair faulty enes rotlier ihan tr¢ai syinplom¥ with iradilional dNxs. For SPGI 5, Iliis approacl) holds immense proinise, il directly lar8ets thL rool ¢￿U$¢ of the disease. Our primary re¥ear¢h collaboration is with the University of Shctfield, home to the Sheftield Inslityle for Translational Neuroscience (SITTaN). where Professor Mimoun A220uz and hi.4 le&ni are pioneering gene replacement strategies specifically for SPG15. These resear¢hers are currently t¢slinE several approaches to deliver functional copies of Ihe SPGIS gene, working ihrough the challenges of targeting the brain and spinal cord effectively. Preclinical studies usiiig validaied cell and animal models are underway to deterniine the most promisin8 path forward. We irc also Slill proud lo be Collaborating with AskBio for another year, 8 global pharnia biote¢l) company specialising in gene therapy, lo support and accelerate the research cfforts at Sheffield. Together, we are moving closer lo identifying a vifiblc thernpy thol could Lhange the lives of SPG15 patients. As part of our growing portn¢rship witli the rese4rcli commurtily, wc were recently inviied lo visit ihe Gene Thcrapy Innovution and Manufacturing Cenlre (GTIMC) in Sheffield, where we met witli Profe.%sor Az20uz. GTIMC is one of Ihree hubs in Ilie UK that will soon be capable of manufacturing 8en¢ Iherapies for rare diseases like SPG15. Tliese centres are cwcial for translating laboratory breAkthroug])s into treatments that Can be tesied in clinical lrials aiid eventually brou8hi to patients. It's important to not¢ that because SPGI 5 is an ultrd-rare condition, it would not havc gained scientific attention without the dedicated efforts of our foundation and our supporters. With so fcw paticnts worldwide. large-s¢al¢ commercial investmenl is unlikely. so we Continue to fundrdise and advocalc (o keep the niomcntum going. It 15 this continued support Ihat allows world-closs scientj5ts to ￿MaIn enga8ed in finding a cure for Maddi an(1 others affecid by this condition. Global Collaboration fn addition lo our work in Ihe UK, we mainiain close lies wieh in¢emaiional researchers. We r¢cenily Iravelled lo Boston Children's Hospital to meet witli the team l¢ading the Natural History Study for SPGI S, und¢r the direction or Dr. Dariu5 Ebrllhiini-Fakhari. This lin￿rtant Study is crcaliiiE a global regislry of SPG15 patieiits, wlii¢h is crilical for understanding the disease's progressioi) over time and preparing for future clinic81 trials. Thanks lo these efforts, many Iiiore patients have now been enrolled, expanding the data available lo scientists worldwide. Looking Ahead The Maddi Foundation remains al the forefTonl of efforLS to bring SPG15 from obscurily into Ihe 5poilib,hi or cutting-edge rescarch. Every step forward, from lalK)raiory breakthroughs to intemalional collai)oraiions. briiig5 US closer lo real hope for affected families. Wilh your Continued support, we will keep piishiny boundaries, funding life-changin8 science, and workin¥ tirelessly to reoch the day when SPG15 is no longF¢r untrealablc. Support and Global Outreach Page 5

THE DDI FOUNDATION REPORT OF TH TRUSTEES FOR THE YEAR EN 31A GUST 2024 At the heart of The Maddi Foundation is our commitment to supporting families affected by SPG I S around Ihe world. As awareness of SPGI 5 grows, more families are finding their way lo us, often tlirough referrals from neurologisis and geneiic speciali51s familiar with Herediiary Spaslic Paraplegias. Our website CODsislently ranks highly ill onliiie Se8￿h¢S for SPGI 5, makiiig il a vitsl point of connection for those newly dia8noscd or seeking guidance. Each family's journey witli SPG15 is unique. but they all sliare a eommon need.. access io accurale infom)atioii, emotioiial support. aiid opportunities to engage in research. Wheii families rea¢h oul lo us, we provide compassionate support and PTacti¢al guidance based on our own experience and knowledge of ihc 8lobal research landscape. One of the most important ways we help is by introdu¢in8 faniilie5 to the SPG15 patient registry and Natur41 History Study led by Dr. Darius Ebrahimi-Fakhari at Boslon Children's Hospital, This inlenialional study plays a critical role in understanding how the disease progresses aiid prepare5 the groundwork for fulure clinical trials. Once families are conncclcd, Ihe Bosion team follows up directly, eiiher through in-p¥rson meetii18s or video consuli&lions. lo explain ihe study, answcr queslions. and orrer suprK)rt tailor¢d to eAch fainily's cir¢urn¥lai)c¢s. By helpin¥ f&imilic5 participate in Iliis research, we nol only provide them with acce¥s lo expert care and knowl¢d¥L bul Iso conlribule lo a 8rowin8 global dalasd thai will be invfjluable for developing and testing future Ir¢a¢menls. We believe that no fan)ily should face ihis diagnosis alone. Through coi)linuous outreaeh, collaboration with healthcare professionals. and mainlaining a .8lroi)g online preKnce. The Maddi Foundation i¥ building a supportive international coniniunily uhilcd by ihc shared goal of findiiig a eure for SPG15. Raising Awaren¢s5 At Thc Maddi Foundation, raising awareness of SPGIS is a corc part of our mission. Our wL'bsile, [www.Iliemaddifoundaiion.com], serve5 as a central liub of infurinalion for families, cliniciuns, ond ies¢archers. It providcs ucccssiblc, upto-date conlenl about SPG15, including curr¢nt research effons, ￿LentifIC rcsourLes, and support Options. We strive to ¢nsure it rei)uins a trusted and valuable source for thc global SPG15 community. To further amplify awareness. we have gromi our presence across major social Inedia plaifonns, including Facebook, Insiagram. and Tiyitter. Tliese channe15 ullow us to share updaic5 on medical research. promoie fundraising events. spotlight patien¢ siories, and keep the public infonned al)oui our ongoing initiatives. Througli digital outweach, we conliiiue to conn¢¢t witl) a broader Judience ond build a supportive online coinniunity. Wc maintain a closc and active partnership with Ihc University of Sheffield. where leading reseurchers arc Working lo develop a gcnc therapy treamlcnt for SPGI 5. As progrcss is Made, we shAre key updales from the resCa￿h team with our supponers through our website and social media channe15. ensuring transparency and engagenient with iliose wlio mukc our work possiblc. In addition lo our UK partnerships, we collaborate with researchers worldwide who are dedic8t¢d lo understanding and treating hereditary spasiic paraplegias. As proud niembers of Ilie Eiirop¢an OrBanisation for Rare Di.sease8 (EURORDIS), we rc8uIArly participate in internaiioiial ¢onfereiices and scientific meeling%. including ihose focused on spaslic paraplegias aiid gene therapy. Wlien in-pcrson ali¢ndanc¢ isn't po&sibl¢. we cngage Ihrough virtual platfonns lo slay connected witli the broader research communily. Cariiia Thurgood. one of our co-founders, has s¢rved on the Board of Directors of the Spaslic Paraple8ia Foundaiion USA since 2019. Her role slrengtheiis our tsYnsatl8ntic collaborations and helps unify global efforts to accelerate researcl) and awareness for SPG15 and related conditions. We remain dedicated lo expanding our knowledge of SPG15 and forgiiig new connections witl) medical reseairhers and in￿1[11l11IOns. By sharing infom)alion. advocatin8 for patients, and supporting collaborative research, we aiin lo brin visibiliiy lo ihis rare condiiion and drive progress toward effeciive trealments. Our Fuiure Goals Page 6

ADDI FOUNDATI REPORT F THE TRUSTEES FOR THE Y REN D31A GU 024 Looking ahead, The Maddi Foundation r¢matns stcadfast in its commitment to acceleratin8 research and expanding 81obal awarcness of SPG I S. Our soals reflect our long-term vision lo not only fiiid a treatment but ultimaiely a cur¢ for this devastaling condilioh. o St￿ng1henln8 Medical Research We will conlinue lo prioritise and fund high-qualily inedical research. while a¢lively expanding our rtetwork or sciditists working on Hereditary Spastic Paraplegia5 and other rare iieurodeB¢neTative discases. Building Strong collaborations across academic and clinical communilies remains Cciilral to our strategy. o Advancing Gcnc Therapy for SPG13 A key objective 15 lo support Ihe next phase of the gene theropy research progrnmine currently undenvdy at the University of Sheffield. Should their approach coniiiiue to show posicive results in SPG 13 ¢ell and animal niodels, we are prepared to fund further development in partnership with th¢ rese8￿h team. This programme remains our most proiiiising avenue toward a targeted treattnent. o Welcoinin¥ New Rescarch Proposals We are actively sceking lo engaBe additional researchers interested in lackling SPG15. All new project proposa15 will be Carefully reviewed ii) consultation with our scientific advisory board. Proposals thai demonstrate scieniific meril and poILiilial lor rLal-world impact will ￿ considered for funding. Our goal is lo sllpport innovative. forward-thinkin¥ rcbcarch thal could lead to transforinaiivc breakthrouglis for individiials living with SPG15. As a foundation focused on an ultra-rare condition. it can be challenging io find long-lerni truslees who ttre boih passion&l¢ and committed. We are pleased to report ihai all CU￿ent members of The Maddi Foundation Board of Trusiee5 have chosen to remain in posi for anoiher year. Their continued support reflects a shared dedication lo our mission and to the fainilies we serve. The tnislees are proud lo be part of thi5 vital work and are fully comrnilled to seeing our vision Ihrough. TokT¢th¢r, with our suppoNLrs, researL'hers, and families, we move forward witl) detcrminaiion and l)ope, driven by the belief thal a cure for SPG15 is within reach. Company Sceretary Independent Examiner Michacl Loinoley Xeinadin South East Ltd Create Busines5 Hub Ground Floor 5 Rayleigh Road Hutton, Brentwood. Essex CM13 IAB Approvcd by order of the board of trn51ees on .........,..,..............,..,.........,.... and signed on ilb behalf by., Mrs C Tlw Pa8e 7

EPEND THE ADDI F NER'S REPOR UNDATION TOTH TRUSTEES OF Independent ex9mlner's report to the trustees of THE MADDI FOUNDATION ('the CompAny') I report to the charity irnstees on my examination of thc accounts of the Company for the year ended 31 August 2024. Responsibllltles and basls of report As the charity's trustees of the Company (and also its directors for ihe purposes of company law) you are responsible for the preparation of the accounls in accordance with the requirements of the Companies Aci 2W6 {'Ihe 2006 Act.). Having satisfied myself Ihat ihe accounts of the Company are not required lo be Ludiled und¢r Part 16 of the 2006 Act and arc eligible for independent examination, I report in respect of my examination of your charitys accounts as Corried out under Section 145 of the Charities Act 2011 ('th¢ 2011 Act,). In carrying out my examination I have followed the Directions given by the Charity Commission under Sectioi) 145(5) (b) of the 2011 Act. Independent examlner's statement I have Complet￿ my examination. I confimi that no matters have come to my alt¢nlion in connection with the examin81ion 8iving m¢ cause to believe: accounting records were not kept in irspe¢t of the Company D5 required by Se¢tioi) 386 of the 2006 Act,. or the accounts do not accord with ihosc record5; or the ac¢oiiiils do not comply wilh the accounlin8 requirements of Seclion 396 of the 2006 Act oiher Ili&n any requiffmei)t Ihat tlie accoui)Is 8ive a true and fair view which is nol a n)atter Considered as part of an independenl examination. or Ihe accounts havc noi been prepared in accordance willi the metliods and prinLipl¢¥ of the Sialemenl of Rttommended Practice for accoui)tinby and reportin¥ by charilie& (applicable to charilies preparinb, tlieir accounls in accordaiice with ihe Finaiicial Reporling Standard applicable in Ilie UK ond Republic of Ireland (FRS 102)), I have no concerns and have Come acros5 no other matters in connection with the examinaiion to which attention sl)ould be drawn in this report in order lo eiiable a proper understanding of the accounts lo be reached. Michael Lomotey. FcbA . Xeinadln South East Lid Create Business Hub Ground Floor 5 Rayleigh Road Hutt¢)n, Brentwood. Es5CX CM13 IAB Dat¢.. Page 8

TH MA DIF UNDATI STATEME T OF FINANCIAL A FOR E YEAR ENDE 31 IVITIES T20 2024 Unrestricted fund 2023 Total fund5 Notes INCOME AND ENDOWMENTS FROM Donations and legacies 12.728 17,515 EXPENDtTURE ON Raising funds 2,S90 1.691 NET INCOME 10.138 15.824 RECONCILIATION OF FUNDS Total funds brought forward 59,167 43,343 TOTAL FUND.8 CARRIED FORWARD C?9.305 59.167 The notes form part of t])ese finaiicial siaiemcnls Page 9

THE MADDI FOUNDATI BALANCE SHEET 2024 Unrestricted nd 2023 Total funds Notes CURRENT ASSETS Cash at bank 69,305 59,167 NETCURRENT ASSETS 69.305 59,167 TOTAL ASSETS LESS CURRENT LIABILITIES 69.305 59.167 ET ASSETS 69,305 59,167 FUNDS Unresiricted funds 69,30S 59,167 TOTAL FUNDS 69,305 59,167 The charitable conipany is entslled to exemption from audii under Section 477 of the Companies Aei 2006 for the year ended 31 AUBUSI 2024. The meinbers have nol required the eonipany to obtain an audit of its financial statements for the year endcd 31 Au8ilSt 2024 in accordance with Se¢iion 476 of th¢ Compllnies Aci 2006. The tNste¢s a¢knowled¥¢ ihcir r￿ponsibIlitIeS for (a) ensuring that the charitable company keeps accountin8 records that comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial 5talern¢nls which give a true and fair view of the state of affairs of the charitsblc company as at the end of each financial year and of ils surplus or deficit for cach financial year in accordance will) (lie rcquirements of Sections 394 and 395 and which otherwise comply with the requirement5 of Ihe Companies Aci 2006 relaling to financial slatemenls, so f&r as applicable to the ¢haritable ¢ornpany. (b) The notes form parl of these fittancial 5tatemcnts Page 10 coniinued...

HE DI UNDATION BALANCE SHEET - contlnued These finan¢ial slatcnients have been prepared in accordance with the provisio￿ appli¢abL¢ to charitable companies subject to Ihe small companies regime. The financial stalements were approved by th¢ Board of Truslces and 8Liihoris¢d for issue . and were signed on it5 behalf by.. on -Thistee A Thw8ood -TnJsteg Mrs V L B138ett-Tn￿t8O The noies form part of these finan¢i41 statements Pagell

THE MADDI FO DATI NOTES TO THE FINANCTAL STATEMENTS FOR THE YEA DED UG 024 ACCOUNTING POLICIES Basis of preparing the Ilnanclal statements The financial stalcmcnts of the charitable company, which i5 a public benefii entiiy under FRS 102, hav¢ been prepared in ae¢ordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charitics: Sratement of Recommended Practice appli¢able to charilics prcparing their accounts in accordance with tl)c Financial Reporting Standard applicable in Ilie UK and Rcpublic of Ireland (FRS 102) (effective l January 2019),, Financial Reporting Standard 102 'The Fin&n¢ial Rcporting Staiidard applicable in the UK and Republic of Ireland, and the Companies Act 2￿6. Tlie financial stateinenls have been prepared under the liistorical cost convention. Income All income is recognised in Ihe Statement of Financial Activities once the charily has enlitlemenl to the funds. it is probablc that the income will be received and t])e amount can be Ineasured reliably. Expendltyre Liabililics arc r¢¢ogniscd as expcndilure J5 500n as ther¢ is a legal or constru¢liv¢ obligatton commiiiing the cl)arity to that expcnditure. it is probable ih81 a transfcr of economic benefits will be required in scttlem¢nt and Ihc amount of the obli8alion can b¢ measured reliably. Expenditure is accounted for on an accruals basis and has been classified under hc8din85 that aggr¢gate all cost related to the cat¢gory. Where ¢osts Cannot be dircctly attribuied io particular headin8S thcy have been all￿ated to a¢iivities on a basis ¢onsislent with Ihe use of resources. Taiktlon Th¢ charity is exempt from corporation lax on its ch￿'[table aclivilies. Fund Accounting Unrestricted funds can be used in accordance witii the charitable objectives at Il)e discretion of the Iruslces. Restricied fvnds can only be used for particular rcstricled purposes within the objects of tlie chariiy. Restrictions hrise when spccified by the donor or when funds are raiscd foi. particular restricted purposes. Furthcr explanation of the nature and purpose of ea¢h fund is included in the notcs to thc finfyncial staicment5. RAISTNC FUNDS Ralslng don4tlons and legacles 2024 2023 Fundraising costs Subs¢riptions Support costs 1.563 37 1.022 85 584 1,600 1,691 Page 12 continued...

THE MADDI UIYD TION NOTLS TO THE FINAN R THE YEAR E ED IAL STATEMENTS - contlnued T 2024 TRUSTEESI REMUNERATION AND BENEFITS Therc were no mistees, remuneralion or other benefits for ihe year ended 31 Augusl 2024 nor for tlie year ended 31 Augusl 2023. Truslees, expenses Trus*e5 wer¢ reinibursed for reasonable expenses properly incurred while serving as Irustees. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES Unrestricted fund INCOME AND ENDOWMENTS FROM Donations and Icgacies 17,515 EXPENDITURE ON Raising fitiids 1,691 NET INCOME 15.824 RECONCtLIATION OF FUNDS Totfil funds brou¥ht forward 43,343 TOTAL FUNDS CARRIED FORWARD 59.167 MOVEMENT Iiy FUNDS Nel moveiiien¢ in funds At 31.8.24 Ai 1.9.23 Unreitrl¢ted funds Gcneral fund 59,167 10,138 69,305 TOTAL FUNDS 59,167 10,138 69.305 Nel movement in funds, incliided in the abov¢ are as folloivs: Incomin r¢sourc¢s ResOU￿e8 expended Movcm¢ni in fiinds Unrestrlcted funds General fund 12,728 (2.590) 10,138 TOTAL FUNDS 12,728 (2,590) 10.138 Page 13 coniinued...

TH MAD FOUNDATION NOTFS TO THE FINANCIAL STATEM NT FOR THE YEAR END 31 AUG 2024 continued MOVEMENT IN FUNDS - eontinued Comparatives for movement In funds Net movement in funds At 1.9.22 31.8.23 Unre$trlcted funds General fund 43,343 15,824 59,167 TOTAL FUNDS 43.343 15.824 59.167 Comparative net movcmeni in funds, includcd in Ihe above are as follows.. Incoming resources Resources expcnded Movcin¢nt in funds Unre5trlct¢d funds General fund 17.515 (1,691) 15,824 TOTAL FUNDS 17,515 (1,691) 15.824 A current ycar 12 months and prior y￿r 12 months ¢ombin¢d position is as follows: Net movemeni in funds At 31.8.24 Al 1.9.22 Unrestrleted funds General fund 43.343 25.962 69,305 TOTAL FUNDS 43,343 25,962 69,305 A current year 12 Inonth5 and prior year 12 months combined i)et movement in funds, included in the above are as follows- Incoming resour¢e5 Resources expciided Movement in fvJ)ds Unrestrlcted funds Gencrnl fund 30,243 (4.281) 25,962 TOTAL FUNDS 30.243 (4,281) 25,962 Page 14 continued...

THEM DI OUNDATION NOTES TO THE FINANCIAL STA TEMEwfs- contlnued R THE YEAR ND UGUST 2024 RELATED PARTY DISCLOSURES There were no r¢lated party transactions for the year ended 31 August 2024. Page 15

HE MADDI FOUN ION DETAILED FOR THE YE TEME1￿ OF FINANCIAL A NDED AU ou IVITIES 2024 2023 TNCOME AND ENDOWMENTS Donatlons and legaele8 Donations 12,728 17,515 Tolal incomlng resources 12,728 17,515 EXPENDITURE RAislng donatlons and legAcles Fundraising costs sUb￿rIptIOns 1,563 37 1,022 85 1,600 1.107 Support costs Finance Bank charges 216 216 Informatlon technology Webs-ilc expensc¥ 302 Othcr Sundries 673 66 Toial resources expended 2,590 1,691 Net Income 10.138 15,824 This page do¢s not form part ofthe slatulory financial statements Page 16